Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
News|Articles|June 5, 2025
Pharmacy Practice in Focus: Oncology
- July 2025
- Volume 7
- Issue 5
ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer
Author(s)Gillian McGovern, Editor
Compared with standard of care, camizestrant in combination with a CDK4/6 inhibitor shows promise in enhancing progression-free survival (PFS) for patients with advanced breast cancer.
Advertisement
Advertisement
Camizestrant (AstraZeneca), used in combination with a CDK4/6 inhibitor, resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when used as a first-line treatment in patients with ESR1-mutated hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. These findings, which were presented at the 2025 American Society of Clinical Oncology in Chicago, Illinois, represent a potential new treatment strategy to improve and optimize patient outcomes in the first-line setting.1
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
Advertisement
Advertisement